Work

Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.12055

Authors: Hua-Xin Gao, Sabyasachi Bhattacharya, Christopher Jon Matheny, Niranjan Yanamandra, Shu-Yun Zhang, Heidi Emerich, Yufeng Li, Paul Bojczuk, Hong Shi, Wei Wang, Christopher Hopson, Tihui Fu, James Patrick Allison, Padmanee Sharma, James F . Smothers, Roopa Srinivasan, Axel Hoos

Institutions: GlaxoSmithKline (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891308638

Cites:

Cited by: 11

Related to: 10